Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

85.45 -0.19 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 390,176
Open 85.51
Bid (Size) 83.26 (1)
Ask (Size) 87.58 (1)
Prev. Close 85.64
Today's Range 84.38 - 86.05
52wk Range 58.14 - 93.45
Shares Outstanding 94,324,313
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile. 
Via Benzinga
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
Via Benzinga

Performance

YTD
+21.22%
+21.22%
1 Month
+10.84%
+10.84%
3 Month
+14.91%
+14.91%
6 Month
+28.75%
+28.75%
1 Year
+44.20%
+44.20%

More News

Read More
Earnings Preview For Intra-Cellular Therapies
Via Benzinga
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
Via Benzinga
Expert Ratings For Intra-Cellular Therapies
Via Benzinga
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Via Benzinga
Where Intra-Cellular Therapies Stands With Analysts
Via Benzinga
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Via Benzinga
Analyst Ratings For Intra-Cellular Therapies
Via Benzinga
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
Via Benzinga
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Via Benzinga
Exposures Product Safety
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
Via Investor's Business Daily
The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
Via InvestorPlace
How Is The Market Feeling About Intra-Cellular Therapies?
Via Benzinga
ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
3 Biotech Stocks With Skyrocketing Potential: April 2024
Via InvestorPlace
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.